Correction to: Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia

Correction to: Clinical and Experimental Nephrology 10.1007/s10157-019-01811-9

In the original publication of the article the presentation of Table 1 was incorrectly published. The corrected table (Table 1) is given below.

Table 1.

Clinical trials of dotinurad

References	Clinical trails gov ID	Study objectives	Subjects or patients	Dotinurad dose (day)	Dosing period
[23]	NCT02344862	Dose response, optimal dose and safety (phase 2a)	Hyperuricemia	0.25 → 0.5 → 1,2,4 mg placebo	8 weeks
[24]	NCT02416167	Dose response, optimal dose and safety (phase 2b)	Hyperuricemia	0.25 → 0.5 → 0.5,1,2,4 mg placebo	12 weeks
[25]	NCT03006445	Long-term efficacy and safety	Hyperuricemia	0.5 → 1→2 mg 0.5 → 1→2 → 4 mg	34 or 58 weeks
[26]	NCT02344875	PK, PD, and safety in elder subjects	Elderly	1 mg	Single dose
[27]	NCT02347046	PK, PD, and safety in patients with CKD	CKD Healthy	1 mg	Single dose
[28]	NCT03306667	PK, PD, and safety in patients with liver damage	Liver disease Healthy	4 mg	Single dose
[30]	NCT03100318	Non-inferiority test to benzbromarone and evaluation of safety	Hyperuricemia	0.5 → 1→2 mg benzbromarone 25 → 50 → 50 mg	14 weeks
[31]	NCT03372200	Non-inferiority test to febuxostat and evaluation of safety	Hyperuricemia	0.5 → 1→2 mg febuxostat 10 → 20 → 40 mg	14 weeks
[32]	NCT03350386	PK and safety of oxaprozin in combination (Drug interaction)	Healthy	4 mg → oxaprozin 600 mg → 4 mg + oxaprozin 600 mg	Single dose 6 days
[33]	NCT02837198	PD, PK, and safety in patient groups classified into G1 and G2	G1: overproduction type, G2: underexcretion type	1 mg → 1 mg + topiroxostat 80 mg	7 days
[34]	NCT03375632	PD and safety in patient groups classified into G1 and G2	G1 and G2	0.5 → 1→2 → 4 mg	14 weeks

PK pharmacokinetics, PD pharmacodynamics, UA uric acid, CKD chronic kidney disease

The original article has been corrected.